Analysts Are Bullish on Top Healthcare Stocks: Boston Scientific (BSX), Teladoc (TDOC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX – Research Report), Teladoc (TDOC – Research Report) and Thermo Fisher (TMO – Research Report) with bullish sentiments.

Boston Scientific (BSX)

RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Boston Scientific yesterday and set a price target of $70.00. The company’s shares closed last Wednesday at $63.26, close to its 52-week high of $64.49.

According to TipRanks.com, Chadha is a 2-star analyst with an average return of 0.1% and a 45.9% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Edwards Lifesciences.

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $68.39, representing a 6.9% upside. In a report issued on January 16, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Teladoc (TDOC)

In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on Teladoc, with a price target of $30.00. The company’s shares closed last Wednesday at $19.43.

According to TipRanks.com, Dodge has 0 stars on 0-5 stars ranking scale with an average return of -7.3% and a 39.9% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Privia Health Group, Avid Bioservices, and Health Catalyst.

Currently, the analyst consensus on Teladoc is a Moderate Buy with an average price target of $24.13.

Thermo Fisher (TMO)

RBC Capital analyst Conor McNamara maintained a Buy rating on Thermo Fisher yesterday and set a price target of $642.00. The company’s shares closed last Wednesday at $538.98.

According to TipRanks.com, McNamara is ranked 0 out of 5 stars with an average return of -8.5% and a 42.7% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS.

Thermo Fisher has an analyst consensus of Moderate Buy, with a price target consensus of $590.08, representing a 4.8% upside. In a report issued on January 29, Nephron also upgraded the stock to Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BSX:

• Boston Scientific Announces Key Executive Appointments
• Boston Scientific (NYSE:BSX) Surges on Stellar Q4 Results
• Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
• Boston Scientific sees FY24 adjusted EPS $2.23-$2.27, consensus $2.24
• Boston Scientific sees Q1 EPS 50c-52c, consensus 52c